Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications

Infertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8-12% of couples trying to conceive globally. Female factor infertility can be subdivided into the following broad categories: ovulatory dysfunction, fallopian tubal disease, uterine causes, and oocyte quality. Hyperprolactinemia causes ovulary dysfunction along with other hormonal abnormalities, such as decreased estrogen, which can lead to infertility. In this regard, antipsychotics are commonly used for both schizophrenia and bipolar disorder. The use of these medications can be associated with hyperprolactinemia and hyperprolactinemia associated infertility. Antipsychotic-induced hyperprolactinemia occurs through blockade of D<sub>2</sub> receptors on lactotroph cells of the anterior pituitary gland. Discontinuation of the hyperprolactinemia-inducing antipsychotic is an option, but this may worsen the patient's psychosis or mood. If antipsychotics are determined to be the culprit of infertility, the degree of hyperprolactinemia symptoms, length of treatment with the antipsychotic, and risk of relapse should be assessed prior to discontinuation, reduction, or switching of antipsychotic medications. The treatment of a women's mental health and her desire to have children should always be considered as treatment may influence fertility while on the medication.

Authors

Institutions

Publication Details

Journal
Psychopharmacology Bulletin
Published
2025-08-12
DOI
https://doi.org/10.64719/pb.4396
Citations
31
Primary Topic
Pharmacological Effects and Toxicity Studies
Type
article
Field-Weighted Citation Impact
27.95
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications

Amber N. Edinoff, Nancy S Silverblatt, Hayley Vervaeke, Andrew Garcia et al.
31 citations
Psychopharmacology Bulletin
Pharmacological Effects and Toxicity Studies
27.95
article

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications

Amber N. Edinoff, Nancy S Silverblatt, Hayley Vervaeke, Andrew Garcia, Eden Girma, Omar Viswanath, Alan D. Kaye, Treniece N. Eubanks, Jessica S. Kaye, Elisa E Neuchat, Cassidy C Horton, Ivan Urits, Adam M. Kaye, Giustino Varrassi
article en
31 citations

Abstract

Infertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8-12% of couples trying to conceive globally. Female factor infertility can be subdivided into the following broad categories: ovulatory dysfunction, fallopian tubal disease, uterine causes, and oocyte quality. Hyperprolactinemia causes ovulary dysfunction along with other hormonal abnormalities, such as decreased estrogen, which can lead to infertility. In this regard, antipsychotics are commonly used for both schizophrenia and bipolar disorder. The use of these medications can be associated with hyperprolactinemia and hyperprolactinemia associated infertility. Antipsychotic-induced hyperprolactinemia occurs through blockade of D<sub>2</sub> receptors on lactotroph cells of the anterior pituitary gland. Discontinuation of the hyperprolactinemia-inducing antipsychotic is an option, but this may worsen the patient's psychosis or mood. If antipsychotics are determined to be the culprit of infertility, the degree of hyperprolactinemia symptoms, length of treatment with the antipsychotic, and risk of relapse should be assessed prior to discontinuation, reduction, or switching of antipsychotic medications. The treatment of a women's mental health and her desire to have children should always be considered as treatment may influence fertility while on the medication.

Psychopharmacology BulletinVol. 51(2)
Louisiana State University in Shreveport (US)
Good health and well-being
Openalex Percentile: Top 0%
Pharmacological Effects and Toxicity Studies
27.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.